Electronic Biosensors Enable Rapid Detection of Early Cancer Cells

CLEVELAND, July 15, 2025 — IdentifySensors Biologics, a leader in digital diagnostic technologies, has announced significant advancements in its electronic biosensor technology, with the capability to rapidly detect early-stage cancer cells. This breakthrough could revolutionize molecular cancer screening and diagnosis, particularly in home healthcare settings.

The company’s diagnostic platform, known as Check4, utilizes electronic biosensors initially designed for pathogen detection. CEO Dr. Greg Hummer stated, "We have been optimistic that our electronic biosensors could detect cancer, but our research this month supports that theory, at least in preliminary studies and before the FDA reviews the process." The announcement comes as IdentifySensors moves toward commercialization and regulatory review of its platform, which has garnered interest from major pharmaceutical companies for its potential applications in cancer diagnostics.

The Check4 system is built around a reusable portable Bluetooth device and a single-use cartridge that can process both saliva and blood samples. This innovative technology aims to deliver test results directly to healthcare systems and patients via a mobile application, eliminating the need for traditional laboratory setups and lengthy waiting periods.

"This platform represents a new class of diagnostics utilizing low-cost electronic circuits to analyze bodily fluids, which significantly reduces the logistical challenges of conventional testing methods," explained Dr. Linda Roberts, a leading researcher in molecular diagnostics at Stanford University. In a study published in the Journal of Clinical Diagnostics in April 2025, Roberts noted the potential for such technologies to enhance accessibility to cancer screenings, particularly in underserved populations.

The biosensor technology operates by producing electrical signals in response to the detection of specific DNA or RNA sequences associated with cancer cells. These signals are then captured digitally and analyzed through a proprietary cloud-based algorithm, allowing for rapid interpretation of results. According to a recent report by the National Cancer Institute, early detection significantly improves cancer survival rates, underscoring the importance of innovations like Check4 in public health.

In terms of regulatory progress, IdentifySensors has initiated a pre-Emergency Use Authorization (EUA) submission for its platform to the U.S. Food and Drug Administration (FDA). As of July 2025, the FDA is reviewing the submission, which could pave the way for widespread clinical application of the technology.

Manufacturing of the Check4 devices has commenced in the United States, with 26 patents already issued to IdentifySensors and additional patents pending. The implications of this technology extend beyond cancer detection; it may also facilitate the diagnosis of various infectious diseases, thereby enhancing public health responses to emerging health crises.

Dr. Hummer emphasized the broader vision for Check4, stating, "As this technology progresses, we aim to make molecular cancer screening widely affordable and accessible for individuals at home. The potential for early detection could drastically alter the landscape of cancer treatment and improve patient outcomes."

Experts in the field express cautious optimism regarding the technology's future. Dr. Emily Chen, a cancer epidemiologist at Johns Hopkins University, remarked, "While the preliminary findings are promising, further clinical validation is essential before we can fully endorse this technology for routine cancer screening."

The ongoing advancements in electronic biosensor technology signify a paradigm shift in molecular diagnostics, with the potential to democratize access to essential health services. As the FDA continues its review of IdentifySensors’ submission, the medical community eagerly anticipates the outcomes that could redefine cancer screening protocols.

### About IdentifySensors Biologics IdentifySensors Biologics is a nanobiotech company focused on transforming molecular diagnostics from a laboratory-centered model to a more accessible, low-cost, portable platform. Their innovations leverage advanced nanomaterials and bioinformatics to enhance diagnostic capabilities across various medical fields. For more information, visit [www.identifysensors.com](http://www.identifysensors.com).